AFSymposium 24: LAA Exclusion in Addition to PVI for Non-paroxysmal AFIB

  • Dhanunjaya Lakkireddy
  • 20.02.24

AFSymposium 2024 — In this interview, investigator, Dr Dhanunjaya Lakkireddy (Kansas City Heart Rhythm Institute, US) shares the key findings from the aMAZE Continued Access Protocol (AtriCure).

This study is the extension of the aMAZE Trial investigation in the form of a nested, non-randomised registry. The study looked at the LARIAT System, which percutaneously isolates and ligates the left atrial appendage (LAA) as an add-on to pulmonary vein isolation (PVI) for persistent or longstanding persistent atrial fibrillation (AF).

1. What is the background to this study?
3. What are the findings to date?
4. Which patients would benefit from LAA exclusion?
5. What is the take-home message for practice?
6. What further research is required?

Recorded on-site at AF Symposium 2024, Boston.

Support: This is an independent interview conducted by Radcliffe Cardiology.

Editor: Mirjam Boros
Videography: David Ramsey, Bard Wilson, William Cadden